VALBIOTIS SA: Valbiotis recognized by the 2025 Top Santé Award for Valbiotis Plus® Serenity, an innovative solution for emotional balance

Valbiotis recognized by the 2025 Top Santé Award
for Valbiotis Plus® Serenity,
an innovative solution for emotional balance

La Rochelle, Thursday, December 18, 2025 (5:40 PM CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the design and distribution of scientifically tested dietary supplements to support health at every stage of life, announces its receipt of the 2025 Top Santé Award for its product Valbiotis Plus® Serenity at the 6th edition of the Top Santé Awards held yesterday evening by the reference media outlet Top Santé.

This award honors the most remarkable innovations, selecting one product per category from 19 health areas, as chosen by a panel of specialized journalists and independent health experts. Products are evaluated against strict criteria, including proven efficacy, health contribution, ease of use, ethics, integrity, innovation and originality.

Recognition of Valbiotis’ distinctive scientific model

This award serves as an external acknowledgment of Valbiotis’ scientific excellence throughout the entire process, from research and formulation to production and commercialization, in line with the highest quality standards.

Valbiotis Plus® Serenity stands out for its high‑value formula designed to address real health needs, driven by a science‑based, innovative and ethical approach at the heart of Valbiotis’ DNA.

“This Top Santé award confirms our ability to turn demanding scientific research into practical solutions that meet health needs still insufficiently addressed. It strengthens  the expertise and visibility of the Valbiotis Plus® range, a strategic pillar of our growth,” said Sébastien Peltier, CEO of Valbiotis.

A positioning aligned with a structural public health challenge

This recognition comes amid a significant decline in mental well-being in France.

According to the OpinionWay[1] study for the Ramsay Santé Foundation published in 2025, 59% of French people report feeling stressed compared with 51% in 2017, with higher prevalence among women and young adults. In response to this structural trend, Valbiotis Plus® Serenity meets the growing demand for natural, effective and scientifically validated solutions, positioning Valbiotis in a segment with strong growth potential.

Valbiotis Plus® Serenity joins the “Stress, Metabolism and Sleep” program developed by Valbiotis as part of this momentum. This program brings together solutions dedicated to emotional and metabolic health, including Valbiotis Pro® Metabolic Health (TOTUM•63), as part of a comprehensive and consistent approach to health concerns that often occur together, without claiming any therapeutic effect.

This Top Santé 2025 award ultimately highlights one of the flagship products in the Valbiotis Plus range, demonstrating our ability to deploy scientific innovations recognized by independent experts, in line with our development strategy.

About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

Caroline LAMBERTI

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial Communication / Seitosei.Actifin 

Marianne PY

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Press Relations / Seitosei.Actifin 
Anne-Claire TATON

+33 6 02 12 25 18 

anne-claire.taton@seitosei-actifin.com

Name: Valbiotis
ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.

[1] https://presse.ramsaygds.fr/communique/224977/Plus-de-4-Francais-sur-10-constatent-augmentation-de-leur-stress-ces-3-dernieres-annees-La-Fondation-Ramsay-Sante-devoile-resultats-de-deuxieme-edition-de-observatoire-du-stress?cm=1